House of Representatives



General Assembly

File No. 2

January Session, 2021

House Resolution No. 7

House of Representatives, January 29, 2021

The House Committee on Judiciary reported through REP. STAFSTROM of the 129th Dist., Chairperson of the Committee on the part of the House, that the resolution ought to be adopted.

RESOLUTION APPROVING THE SETTLEMENT AGREEMENT IN ROBERT BARFIELD, ET AL. V. ANGEL QUIROS, IN HIS OFFICIAL CAPACITY AS COMMISSIONER, CONNECTICUT DEPARTMENT OF CORRECTION.

Resolved by this House:

- 1 That the provisions of the settlement agreement in the action <u>Robert</u>
- 2 Barfield, et al. v. Angel Quiros, in his official capacity as Commissioner,
- 3 <u>Connecticut Department of Correction</u>, United States District Court of
- 4 Connecticut, Civil Action No. 3:18-CV-1198 (MPS), dated November 6,
- 5 2020, requiring expenditure from the General Fund budget in excess of
- 6 two million five hundred thousand dollars and submitted by the
- 7 Attorney General to this Assembly for approval in accordance with
- 8 section 3-125a of the general statutes, are approved.

JUD House Favorable

HR7 / File No. 2

HR7 File No. 2

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note

State Impact:

Agency Affected	Fund-Effect	FY 20 \$	FY 21 \$	FY 22 \$
Correction, Dept.	GF - Cost	7,036,375	20,112,500	10,900,000

Note: GF=General Fund

Municipal Impact: None

Explanation

This settlement requires the Department of Correction (DOC) to provide hepatitis C (HCV) screening and treatment to all inmates until March 1, 2022 and pay the fees and costs for the class counsel resulting in the costs described below.

FY 20:

The DOC spent \$7.0 million on HCV testing and treatment.¹

FY 21:

The DOC was appropriated \$20 million for HCV testing and treatment² and pursuant to the settlement is required to pay \$112,500 in attorneys' fees and costs for class counsel.

FY 22:

HVC testing and treatment is anticipated to cost the agency

HR7 / File No. 2

_

¹ \$10.1 million was appropriated for HCV testing and treatment within the Inmate Medical Services (IMS) account in FY 20 and \$7.0 million was expended. The remaining balance was carried forward into FY 21 pursuant to CGS Sec. 4-89(c). The total carry forward for the IMS account totaled \$7.8 million and the entire carry forward may or may not be used for HCV.

² As of 10/31/20 the DOC has spent \$2.9 million on HCV testing and treatment in FY 21.

HR7 File No. 2

approximately \$10.9 million until March 1, 2022, which is the end of the settlement agreement. 3

The Out Years

None.

 $^{\rm 3}$ Full-year HCV testing and treatment is estimated to be \$18.7 million per year.

HR7 / File No. 2